RT Journal Article
SR Electronic
T1 Impact of Nasopharyngeal Specimen Quality on SARS-CoV-2 Test Sensitivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.09.20246520
DO 10.1101/2020.12.09.20246520
A1 Richard-Greenblatt, Melissa
A1 Ziegler, Matthew J.
A1 Bromberg, Valerie
A1 Huang, Elizabeth
A1 Abdallah, Hatem
A1 Tolomeo, Pam
A1 Lautenbach, Ebbing
A1 Glaser, Laurel
A1 Kelly, Brendan J.
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.09.20246520.abstract
AB Background The SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) cycle of threshold (Ct) has been used to estimate quantitative viral load, with the goal of targeting isolation precautions for individuals with COVID-19 and guiding public health interventions. However, variability in specimen quality can alter the Ct values obtained from SARS-CoV-2 clinical assays. We sought to define how variable nasopharyngeal (NP) swab quality impacts clinical SARS-CoV-2 test sensitivity.Methods We performed amplification of a human gene target (β-actin) in parallel with a clinical RT-PCR targeting the SARS-CoV-2 ORF1ab gene for 1311 NP specimens collected from patients with clinical concern for COVID-19. We evaluated the relationship between NP specimen quality, characterized by high Ct values for the human gene target β-actin Ct, and the probability of SARS-CoV-2 detection via logistic regression, as well as the linear relationship between SARS-CoV-2 and β-actin Ct.Results Low quality NP swabs are less likely to detect SARS-CoV-2 (odds ratio 0.654, 95%CI 0.523 to 0.802). We observed a positive linear relationship between SARS-CoV-2 and β-actin Ct values (slope 0.169, 95%CI 0.092 to 0.247). COVID-19 disease severity was not associated with β-actin Ct values.Conclusions Variability in NP specimen quality accounts for significant differences in the sensitivity of clinical SARS-CoV-2 assays. If unrecognized, low quality NP specimens, which are characterized by a low level of amplifiable human DNA target, may limit the application of SARS-CoV-2 Ct values to direct infection control and public health interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementBJK, MJZ, and EL are supported in part by a CDC Cooperative Agreement FOA#CK16-004 "Epicenters for the Prevention of Healthcare Associated Infections". BJK is supported by the National Institute for Allergy and Infectious Diseases (K23 AI121485 and L30 AI120149). MJZ is supported by the National Institute for Allergy and Infectious Diseases (K23 AI143925).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A waiver of informed consent was granted by the University of Pennsylvania Institutional Review Board (IRB protocols #843085 & #843274).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData, analysis scripts, and model code are available at https://github.com/bjklab/Impact-of-NP-Specimen-Quality-on-SARS-CoV-2-Test-Performance https://github.com/bjklab/Impact-of-NP-Specimen-Quality-on-SARS-CoV-2-Test-Performance